An injectable plant extract used for a century as an add-on to conventional cancer care, mainly in Europe. Generally safe, with injection-site reactions and mild flu-like symptoms most common. The clearest benefit is better quality of life and less fatigue during treatment; a survival benefit is unsettled and tumor shrinkage is unproven. It complements standard care, not replaces it. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Eosinophils | ~0.0–0.5 ×10⁹/L | Gauges immune activation from therapy |
| Lymphocytes | ~1.5–3.5 ×10⁹/L | Reflects immune capacity to respond |
| C-reactive protein (CRP) | <1–3 mg/L at baseline | Interprets fever and inflammatory reactions |
| CA-125 | Trend over absolute value | Tracks disease activity where relevant |
| CEA | Trend over absolute value | Tracks disease activity where relevant |
| Body temperature | <38 °C | Guides dosing and detects fever |
Cadence: Local reactions and temperature at each dose step (weekly early on); blood counts every few weeks; tumor markers and imaging every 8–12 weeks